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Import and spread of extended-spectrum β-lactamase-
producing Enterobacteriaceae by international travellers 
(COMBAT study): a prospective, multicentre cohort study
Maris S Arcilla*, Jarne M van Hattem*, Manon R Haverkate, Martin C J Bootsma, Perry J J van Genderen, Abraham Goorhuis, Martin P Grobusch, 
Astrid M Oude Lashof, Nicky Molhoek, Constance Schultsz, Ellen E Stobberingh, Henri A Verbrugh, Menno D de Jong, Damian C Melles, John Penders
Summary
Background International travel contributes to the dissemination of antimicrobial resistance. We investigated the 
acquisition of extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-E) during international travel, 
with a focus on predictive factors for acquisition, duration of colonisation, and probability of onward transmission.
Methods Within the prospective, multicentre COMBAT study, 2001 Dutch travellers and 215 non-travelling 
household members were enrolled. Faecal samples and questionnaires on demographics, illnesses, and behaviour 
were collected before travel and immediately and 1, 3, 6, and 12 months after return. Samples were screened for the 
presence of ESBL-E. In post-travel samples, ESBL genes were sequenced and PCR with specifi c primers for 
plasmid-encoded β-lactamase enzymes TEM, SHV, and CTX-M group 1, 2, 8, 9, and 25 was used to confi rm the 
presence of ESBL genes in follow-up samples. Multivariable regression analyses and mathematical modelling were 
used to identify predictors for acquisition and sustained carriage, and to determine household transmission rates. 
This study is registered with ClinicalTrials.gov, number NCT01676974.
Findings 633 (34·3%) of 1847 travellers who were ESBL negative before travel and had available samples after return 
had acquired ESBL-E during international travel (95% CI 32·1–36·5), with the highest number of acquisitions being 
among those who travelled to southern Asia in 136 of 181 (75·1%, 95% CI 68·4–80·9). Important predictors for 
acquisition of ESBL-E were antibiotic use during travel (adjusted odds ratio 2·69, 95% CI 1·79–4·05), traveller’s 
diarrhoea that persisted after return (2·31, 1·42–3·76), and pre-existing chronic bowel disease (2·10, 1·13–3·90). The 
median duration of colonisation after travel was 30 days (95% CI 29–33). 65 (11·3%) of 577 remained colonised at 
12 months. CTX-M enzyme group 9 ESBLs were associated with a signifi cantly increased risk of sustained carriage 
(median duration 75 days, 95% CI 48–102, p=0·0001). Onward trans mission was found in 13 (7·7%) of 168 household 
members. The probability of transmitting ESBL-E to another household member was 12% (95% CI 5–18).
Interpretation Acquisition and spread of ESBL-E during and after international travel was substantial and worrisome. 
Travellers to areas with a high risk of ESBL-E acquisition should be viewed as potential carriers of ESBL-E for up to 
12 months after return.
Funding Netherlands Organisation for Health Research and Development (ZonMw).
Introduction
Antimicrobial resistance constitutes an increasingly 
important human health hazard worldwide.1 The use of 
antibiotics in human beings and food animals is a well 
established driving force behind increasing resistance.2 
Given the enormous growth of international tourism, 
from 25 million travellers in 1950 to 1·133 billion in 2014,3 
international travel might also contribute substantially to 
the rise in resistance because resistant bacteria or bacterial 
mobile genetic elements carrying resistance genes (eg, 
plasmids) may be rapidly transported between regions.4 
An important part of antimicrobial resistance genes is 
found on plasmids and codes for extended-spectrum β 
lactamase enzymes ([ESBLs] eg, TEM, SHV, and CTX-M) 
and carbapenemases that confer resistance to most 
β-lactam antibiotics.2,4 Additionally, ESBL-producing 
Enterobacteriaceae (ESBL-E) and carba penemase-
producing Enterobacteriaceae (CPE) are typically resistant 
to multiple other antibiotic classes, which leaves few to no 
eff ective antimicrobial agents for prevention and 
treatment of infections.4,5
Previous studies have reported frequent acquisition of 
ESBL-E associated with various predictors and sporadic 
acquisition of CPE among international travellers.6–10 
However, data on ESBL-E colonisation after travel and 
assessment of associated predictors for sustained carriage 
and onward transmission within households are very 
limited. Such data are needed to establish the public 
health risk of the introduction and spread of antimicrobial 
resistance by travellers, and the potential needs and 
measures to monitor or manage these risks. Identifying 
individuals at risk of ESBL-E carriage enables appropriate 
measures to be taken to prevent introduction and spread 
of ESBL-E or CPE and for empirical adjustment of 
antibiotic treatment in individuals to optimise clinical 
care. We investigated the acquisition of ESBL-E during 
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international travel, the associated predictive factors for 
acquisition, duration of colonisation, and onward trans-
mission to household members.
Methods
Study design and participants
The study design and methods have been described in 
detail elsewhere.11 Briefl y, we did a multicentre, 
longitudinal, prospective cohort study involving travellers 
who were followed up from 1–3 weeks before travel 
departure until 12 months after return. To study 
household transmission, we also assessed non-travelling 
household members in the same period.
Eligible participants were adults (age ≥18 years) 
planning to travel for at least 1 week and up to 3 months. 
They were recruited at three outpatient travel clinics 
across the Netherlands from November, 2012, to 
November, 2013. The study was approved by the Medical 
Research Ethics Committee, Maastricht University 
Medical Centre (METC 12-4-093). All participants 
provided written informed consent.
Procedures
Participants were provided with faeces collection kits and 
instructed to self-collect faecal swabs (appendix) before 
and immediately and 1 month after travel. If any of these 
samples contained ESBL-E, the traveller and his or her 
household members were asked to provide further 
samples at 3, 6, and 12 months after travel. If no samples 
were positive for ESBL-E, no additional samples were 
collected. Questionnaires were also collected at all 
timepoints to obtain information on potential risk factors 
for ESBL-E acquisition, including demographics, 
illnesses, and behaviour before, during, and after travel.
Samples were processed immediately after receipt. They 
were inoculated in tryptic soy broth supplemented with 
vancomycin (50 mg/L) to select for Entero bacteriaceae. 
The broth was then subcultured on chromID ESBL 
(bioMérieux, Marcy l’Etoile, France). All morphologically 
distinct colonies were characterised to the species level 
with matrix-assisted laser desorption/ionisation time-of-
fl ight mass spectrometry (Bruker Microfl ex LT, Bruker, 
London, UK). Antibiotic minimum inhibitory 
concentrations were measured with the automated 
susceptibility testing system Vitek 2 (bioMérieux) for all 
Enterobacteriaceae. ESBL production  was phenotypically 
confi rmed by the combination disc diff usion test, 
according to current national Dutch guidelines.12
All phenotypically confi rmed ESBL-E isolates acquired 
during travel were screened for the presence of ESBL 
Research in context
Evidence before this study
We searched PubMed on Aug 17, 2015, with the search terms 
“Gram negative bacteria”, “Enterobacteriaceae”, “Escherichia”, 
”Klebsiella”, ”Salmonella”, “Shigella”, “Yersinia”, “travel”, “tourist”, 
“tourism”, “turista”, “aviation”, “air transport”, “airport”, 
“resistance”, “colonisation”, “antibiotic”, “susceptibility”, 
“carriage”, and “carrier”. We did a systematic review and 
identifi ed 11 eligible studies. We updated this search on 
April 14, 2016, and found no new prospective studies. The 
results of the 11 prospective cohort studies showed high 
acquisition rates of extended-spectrum β-lactamase-producing 
Enterobacteriaceae (ESBL-E) among travellers who had returned 
from southern Asia and northern Africa. Four travellers who 
visited India acquired carbapenemase-producing 
Enterobacteriaceae (CPE). However, whether antibiotic use and 
traveller’s diarrhoea are predictors for ESBL-E acquisition was 
unclear. Moreover, these studies did not suffi  ciently address 
duration of ESBL-E carriage among travellers or onward 
transmission within households. One study asked travellers to 
provide stool samples up to 12 months after return, but duration 
of carriage was defi ned by ESBL phenotype. One other study 
looked at household transmission, but because only 
11 household contacts were included, no reliable conclusion 
could be inferred about the risk of household transmission.
Added value of this study
In this large-scale, longitudinal cohort study, we followed up 
travellers and their non-travelling household members for up 
to 12 months after travel. The large sample size meant that 
we could investigate ESBL-E acquisition among travellers who 
had returned from a large number of countries across the 
world, including those such as Uganda, for which community 
carriage rates of ESBL-E were previously unknown. 
We identifi ed several predictors (some new) for 
ESBL-E acquisition, including factors specifi c to subregions. 
Moreover, we were able to ascertain duration of 
ESBL-E carriage and associated resistance genes, identify 
predictors for sustained colonisation, and to model 
transmission rates mathematically within households.
Implications of all the available evidence
High frequencies of ESBL-E acquisition during travel, 
subsequent sustained carriage, and evidence of onward 
transmission within households show that travellers 
contribute to the emergence and spread of ESBL-E on a global 
scale. Active screening for ESBL-E and CPE and adjustment of 
empirical antimicrobial therapy should be considered for 
returning travellers at increased risk of ESBL-E carriage. 
However, implications for infection prevention and antibiotic 
treatment policies will diff er locally because the degree of 
consequence of acquisition and spread of ESBL-E by travellers 
is highly dependent on local ESBL-E prevalence in the country 
of origin.
See Online for appendix
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genes with microarray, as described previously 
(appendix). The presence of ESBL genes was confi rmed 
by PCR with primers specifi c for CTX-M enzyme groups 
1, 2, 8, 9, and 25 and in-house primer sets. Further 
characterisation by sequencing was done for the most 
prevalent and largest CTX-M groups, 1 and 9. PCR 
confi rmation and sequencing of genes for TEM and SHV 
ESBLs were limited to isolates that had negative 
microarray results for all CTX-M genes. A generic CTX-M 
PCR was done if no ESBL genes were detected by 
microarray, and, if positive, was followed by specifi c PCR 
and sequence confi rmation for the diff erent CTX-M 
groups (appendix). Sequences were compared with those 
in the NCBI GenBank and Lahey databases.
Acquisition was defi ned as the absence of ESBL-E in 
faecal samples before travel and the presence of ESBL-E 
in those obtained immediately after travel, as identifi ed 
by phenotypic tests. Duration of carriage was defi ned by 
the last positive sample harbouring an ESBL of the same 
group (TEM, SHV, or CTX-M group 1, 2, 8, 9, or 25, or a 
combination) as detected immediately after travel. 
Participants with consecutive samples positive for 
ESBL-E were classifi ed as being persistent carriers and 
those with ESBL-E-positive samples interspersed with at 
least one negative sample were classifi ed as being 
intermittent carriers.
Statistical analysis
Incidence proportions and incidence per 100 person-days 
of travel and accompanying 95% CIs for ESBL-E 
acquisition were calculated for each subregion (appendix) 
and country of destination. Incidence per 100 person-days 
of travel was calculated with a maximum likelihood 
method that was based on a constant acquisition rate 
with right-censored and interval-censored data.
Predictors for ESBL-E acquisition were determined by 
logistic regression models that were based on the method 
proposed by Bursac and colleagues13 (appendix) and 
analysed with IBM SPSS Statistics (version 21.0). Results 
are presented as odds ratios (ORs) and 95% CIs. We did 
separate analyses for the subregions of southeast Asia, 
southern Asia, and eastern Africa, as several dietary 
variables (eg, consumption of chicken, barbecue meat, or 
pork) interacted with specifi c travel destination subregions.
Time to decolonisation was assessed with Kaplan-Meier 
survival analyses with right censoring for participants 
whose last provided sample was ESBL-E positive. 
Univariable and multivariable Cox’s regression analyses 
were done to identify predictors associated with de-
colonisation (appendix). Results are presented as hazard 
ratios (HRs) and 95% CIs (HRs <1·00 indicate decreased 
risk of decolonisation and, therefore, increased duration 
of carriage).
A Markov model was used to calculate the probability 
of transmission within households. For computational 
reasons, this model was based on ESBL-E as defi ned by 
phenotypic confi rmation, and only data from households 
consisting of at most fi ve people were included, but these 
accounted for 98% of households. The model took into 
account false-negative results, missing culture results, 
and unobserved colonisation times. The method of 








Male 920 (46·0%) 80 (37·2%)






No education, elementary school, or 
prevocational secondary education 
243 (12·4%) 78 (36·4%)
Vocational secondary education 280 (14·2%) 37 (17·3%)
Senior general secondary education 
or education up to university
200 (10·2%) 45 (21·0%)
Higher professional education 642 (32·7%) 53 (24·7%)
Academic (university) education 595 (30·3%) 38 (17·8%)
Antibiotic use in previous 3 months 
No 1760 (90·1%) 189 (88·3%)
Yes 194 (9·9%) 25 (11·7%)
Travel in past year
None 185 (9·5%) 27 (12·6%)
In Europe 915 (46·9%) 124 (57·7%)
Outside Europe 852 (43·6%) 64 (29·8%)
Chronic disease‡
No 1500 (77·2%) 173 (82·0%)
Yes 443 (22·8%) 38 (18·0%)
Chronic bowel disease‡
No 1912 (97·4%) 212 (99·1%)
Yes 51 (2·6%) 2 (0·9%)
Continent visited during travel§
Asia 1016 (50·8%) NA
Africa 633 (31·6%) NA
America 326 (16·3%) NA
Europe 21 (1·0%) NA
Oceania 5 (0·2%) NA
Duration of index travel (days) 20
(15·0–25·0)
NA
Purpose of index travel
Holiday 1655 (84·2%) NA
Work or internship 161 (8·2%) NA
Visiting family or relatives 82 (4·2%) NA
Other reason 66 (3·4%) NA
Data are number (%) or median (IQR). NA=not applicable. *Some numbers do not 
add up to 2001 because of missing data. †Some numbers do not add up to 
215 because of missing data. ‡Self-reported by traveller or household member. 
§If travellers visited multiple continents, only the main continent visited is 
presented in this table. 
Table 1: Baseline characteristics of travellers and non-travelling 
household members 
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(travellers or non-travelling household members) 
transmit ESBL-E to household members with rate β. 
Transmission from other sources was incorporated by 
the background transmission parameter α. De-
colonisation of ESBL-E occurred with rate γ. Negative 
cultures could be false negative and aff ect the estimate of 
the sensitivity (φ). The specifi city of culture was assumed 
to be 100%. Thus, the probability of transmission from 
an ESBL-E-positive to an ESBL-E-negative person, given 
that the ESBL-E-negative household member did not 
acquire ESBL-E via another route, could be calculated as 
β/(β+γ). Model parameters were simultaneously 
estimated with a maximum likelihood method in 
Mathematica version 9.0. This study is registered with 
ClinicalTrials.gov, number NCT01676974.
Role of the funding source
The funder of the study had no role in the study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had fi nal 
responsibility for the decision to submit for publication. 
Results
2737 travellers were screened for eligibility, of whom 
2001 were included in the study (appendix), with median 
age 50·5 years (IQR 32·8–60·7) and good health before 
travelling in most (table 1). 49 travellers were lost to 
follow-up.
The main purpose for travel was tourism (1655 [84·2%] 
of 1965 travellers) and the median travel duration was 
20 days (IQR 15·0–25·0; table 1). The subregions most 
frequently visited were southeast Asia (n=650), eastern 
Africa (n=287), South America (n=228), and southern 
Asia (n=217). 122 (6·1%) of 2001 travellers were carrying 
ESBL-E before travel, leaving 1879 at risk of ESBL-E 
acquisition. 1847 (98·3%) of these submitted faecal 
samples after travel, among whom 633 had acquired at 
least one ESBL-E during travel (table 2), giving an 
acquisition rate of 34·3% (95% CI 32·1–36·5). From 
these 633 travellers, 859 morphologically diff erent 
ESBL-E strains were isolated (759 Escherichia coli, 67 
Klebsiella pneumoniae, and 33 other species). CTX-M-15 
was the most frequently acquired ESBL gene, being 
found in 338 (53·4%) of 633 travellers (appendix).
ESBL-E were most frequently acquired in southern 
Asia (75·1%, 95% CI 68·4–80·9), followed by central and 
eastern Asia (48·8%, 38·4–59·3; table 2, fi gure 1), but the 
frequency of acquisition varied widely between countries. 
Among the 22 most frequently visited countries, 
acquisition was highest in India (88·6%, 95% CI 
79·8–93·9) and lowest in Suriname (3·6%, 1·0–12·1; 
appendix). Acquisition was also common after travel to 
eastern African countries, such as Uganda (44·4%, 
27·6–62·7, appendix).
In the multivariable logistic regression, antibiotic use 
during travel was the strongest independent predictor for 
ESBL-E acquisition (table 3). To assess the eff ects of 
diff erent antibiotic classes in the model, we exchanged 
the variable antibiotic use during travel (no vs yes) for a 
variable indicating antibiotic class (no antibiotics vs 
β-lactam, or quinolone, or other). Quinolone use was 
most strongly associated with ESBL acquisition (adjusted 
OR 6·0, 95% CI 2·9–12·4), whereas associations were 
non-signifi cant for use of β-lactam (2·2, 0·95–5·14) or 
other antibiotics (1·7, 0·59–2·35). We also detected 
strong associations between ESBL-E acquisition and 
diarrhoea during travel and, particularly, traveller’s 
diarrhoea that persisted on return (table 3). Travellers 

















days of travel 
(95% CI)§
Southern Asia 181 (9·8%) 136 (21·5%) 75·1 (68·4–80·9) 3727 20·6 (11·0) 7·2 (5·9–8·6)
Central and eastern Asia 84 (4·5%) 41 (6·5%) 48·8 (38·4–59·3) 1712 20·4 (10·8) 3·5 (2·5–4·7)
Western Asia 28 (1·5%) 12 (1·9%) 42·9 (26·5–60·9) 305 10·9 (7·5) 5·8 (3·0–9·9)
Northern Africa 81 (4·4%) 34 (5·4%) 42·0 (31·8–52·9) 981 12·1 (5·7) 4·5 (3·1–6·2)
Southeastern Asia 540 (29·2%) 200 (31.6%) 37·0 (33·1–41·2) 12 493 23·1 (11·6) 2·1 (1·8–2·4)
Caribbean and Central America 86 (4·7%) 24 (3·8%) 27·9 (19·5–38·2) 1653 19·2 (12·4) 1·7 (1·1–2·5)
Middle and eastern Africa 205 (11·1%) 57 (9·0%) 27·8 (22·1–34·3) 4060 19·8 (14·3) 1·6 (1·2–2·1)
Western Africa 106 (5·7%) 20 (3·2%) 18·9 (12·6–27·4) 1638 15·5 (11·1) 1·4 (0·8–2·0)
South America 180 (9·7%) 33 (5·2%) 18·3 (13·4–24·6) 4778 26·5 (14·7) 0·8 (0·5–1·1)
Southern Africa 116 (6.3%) 7 (1·1%) 6·0 (2·5–12·0) 2522 21·7 (8·6) 0·3 (0·1–0·6)
Northern America, Europe, and Oceania 17 (1·0%) 1 (<1·0%) 5·9 (1·1–27·0) 292 17·2 (11·3) 0·4 (0–1·6)
ESBL-E=extended-spectrum β-lactamase-producing Enterobacteriaceae. *Numbers do not add up to 1847 because 221 travellers visited more than one subregion (66 with 
ESBL-E acquisition) and destination information was missing for two. †Numbers do not add up to 633 because 66 travellers visited multiple subregions and destination 
information was missing for two. ‡Based on binomial distribution (Wilson’s score interval). §Calculated with the maximum likelihood estimation method based on a 
constant acquisition rate with right-censored and interval-censored data. 
Table 2: Incidence proportion and incidence per 100 person-days of travel for ESBL-E acquisition in Dutch travellers, by subregion 
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were at increased risk of acquiring ESBL-E compared 
with those who had avoided street food vendors, and the 
risk increased further in travellers who consumed food 
from street vendors daily (table 3). Self-reported pre-
existing chronic bowel disease was another notable risk 
factor for ESBL-E acquisition (table 3).
In the separate analyses for three of the visited 
subregions, the consumption of raw vegetables and 
antibiotic use were predictors of ESBL-E acquisition in 
southeastern Asia. In southern Asia, the strongest 
predictors were contact with orphan children and daily 
food consumption at a hostel or guesthouse. In eastern 
Africa, the strongest associations were daily visits to the 
local markets and staying in rural areas (appendix).
Sustained ESBL-E carriage (persistent and intermittent) 
after acquisition was seen in 42·9%, 25·1%, 14·3%, and 
11·3% of travellers at 1, 3, 6, and 12 months after return, 
respectively. Most of these participants were continuously 
colonised (appendix). The median duration of post-travel 
colonisation was 30·0 days (95% CI 28·9–33·1, fi gure 2). 
ESBL-producing K pneumoniae and travel to western Asia 
were associated with the shortest times to decolonisation. 
Travellers who acquired a CTX-M group 9 ESBL had a 
signifi cantly increased risk of sustained carriage compared 
with travellers who acquired a CTX-M group 1 ESBL 
(appendix).
Of 215 non-travelling household members included in 
the study, 63 were ESBL-E negative at baseline and 
shared households with people who acquired ESBL-E 
while travelling. Additionally, 105 co-travellers who were 
ESBL-E negative immediately after return shared 
households with travellers who acquired ESBL-E. Thus, 
168 household members (in 152 households) were at risk 
of ESBL-E transmission. Evidence of onward trans-
mission within households was found in 13 (7·7%) of 
these 168 household members (ten co-travellers and 
three non-travelling household members, appendix), 
who had one or more follow-up isolates with the same 
ESBL group (TEM, SHV, CTX-M group 1, 2, 8, 9, or 25) as 
had been acquired by the index traveller.
We subsequently used a Markov model to estimate the 
transmission rate of ESBL-E after introduction into a 
household. We included 3330 people from 1542 house-
holds in the estimation of probability of transmission of 
ESBL-E after introduction. 381 households consisted of 
one person, 774 of two people, 187 of three, 160 of four, and 
40 of fi ve. Person-to-person transmission was estimated 
to occur at a rate of 0·0013 (95% CI 0·0005–0·0024) per 
colonised person per day, with background transmission 
occurring at a rate of 0·00073 (0·00054–0·0009) per day. 
The decolonisation rate was 0·010 (0·0092–0·011) per 
day. The sensitivity of the screening process was 90% 
(86–93). Thus, the probability of transmission from an 
ESBL-E-positive to an ESBL-E-negative person in the 
household was 12% (5–18).
Discussion
Results from this large cohort study of travellers indicated 
that the risk of ESBL-E acquisition during travel is high, 
especially during travel to Asia and northern Africa. 11·3% 
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of travellers who acquired EBSL-E remained colonised at 
12 months after return, and the estimated probability of 
onward transmission within households was 12%. Other 
important predictors for ESBL-E acquisition during travel 
were antibiotic use, traveller’s diarrhoea that persisted 
after return, and pre-existing chronic bowel disease.
The frequency with which ESBL-E was imported by 
travellers is worrisome. 75·1% of travellers to southern 
Asia and 40–50% of those to central or eastern Asia, 
western Asia, and northern Africa acquired ESBL-E while 
travelling. Additionally, in central and eastern Africa, 
frequency of ESBL-E acquisition was substantial in some 
countries, particularly Uganda (44·4%). So far, data on 
acquisition among travellers to countries in central and 
eastern Africa have been very limited. Additionally, we 
have previously shown acquisition of carbapenemases 
and plasmid-mediated mcr-1 colistin-resistance genes in, 
respectively, fi ve and six travellers in this study cohort.14,15
Only two of six studies that previously did multivariable 
risk factor analysis identifi ed antibiotic use and traveller’s 
diarrhoea as signifi cant travel-associated predictors for 
ESBL-E acquisition,6–8 which probably refl ects limited 
power to do extensive risk factor analysis. Self-reported pre-
existing chronic bowel disease (mainly infl ammatory bowel 
disease, irritable bowel syndrome, and coeliac disease) was 
a new predictor for ESBL-E acquisition in this study. 
Antibiotic use, traveller’s diarrhoea, and chronic bowel 
disease have well established associations with dysbiosis of 
the gut microbiota.16–18 A dysbiosis-induced reduction in 
colonisation resistance being the underlying biological 
mechanism through which these factors predispose to 
ESBL-E acquisition is, therefore, conceivable. Antimicrobial 
agents have substantial eff ects on the gut microbiota, 
which mainly manifest as decreased colonisation resistance 
resulting in consequent emergence of pathogenic or 
antibiotic-resistant strains.19 In this study we found that, 
Number of travellers 
at risk (n=1847)* 
Number of travellers 
who acquired ESBL-E 
(n=633)† 
Odds ratio (95% CI)‡ p value Adjusted odds ratio 
(95% CI)§ 
p value
Pre-existing bowel disease 
No 1793 (97·3%) 606 (33·8%) 1·00 ·· 1·00 ··
Yes 50 (2·7%) 24 (48·0%) 2·34 (1·26–4·34) 0·007 2·10 (1·13–3·90) 0·019
Beach holiday 
No 1404 (76·1%) 504 (35·9%) 1·00 ·· 1·00 ··
Yes 441 (23·9%) 127 (28·8%) 0·72 (0·55–0·93) 0·010 0·73 (0·56–0·95) 0·021
Traveller’s diarrhoea¶
No 1085 (60·1%) 329 (30·3%) 1·00 ·· 1·00  ··
During travel 593 (32·8%) 235 (39·6%) 1·56 (1·24–1·96) <0·001 1·42 (1·12–1·80) 0·003
Immediately after travel 41 (2·3%) 14 (34·1%) 1·19 (0·58–2·44) 0·640 1·3 (0·63–2·68) 0·477
During travel and immediately 
after travel
87 (4·8%) 44 (50·6%) 2·42 (1·50–3·91) <0·001 2·31 (1·42–3·76) 0·001
Antibiotic use during travel||
No 1697 (92·8%) 553(32·6%) 1·00  ·· 1·00  ··
Yes 132 (7·2%) 73 (55·3%) 2·65 (1·80–3·91) <0·001 2·69 (1·79–4·05) <0·001
Attendance of large (religious) gathering 
No 1744 (94·6%) 595 (34·1%) 1·00 ·· 1·00  ··
Yes 100 (5·4%) 36 (36·0%) 0·56 (0·34–0·92) 0·020 0·57 (0·34–0·94) 0·028
Daily hand hygiene before meals 
None 782 (42·4%) 265 (33·9%) 1·00 ·· 1·00  ··
Clean with alcohol 161 (8·7%) 69 (42·9%) 1·03 (0·71–1·51) 0·870 0·97 (0·66–1·44) 0·885
Clean with soap 666 (36·1%) 200 (30·0%) 0·82 (0·64–1·04) 0·100 0·77 (0·60–0·99) 0·044
Clean with alcohol and soap 235 (12·7%) 97 (41·3%) 1·03 (0·74–1·44) 0·860 1·12 (0·79–1·59) 0·518
Meal at street food stalls during travel  
Never 1248 (67·7%) 386 (30·9%) 1·00 ·· 1·00  ··
Occasionally 513 (27·8%) 205 (40·0%) 1·37 (1·08–1·73) 0·010 1·33 (1·04–1·71) 0·022
Daily 83 (4·5%) 40 (48·2%) 2·09 (1·30–3·38) 0·003 1·78 (1·07–2·95) 0·025
ESBL-E=extended-spectrum β-lactamase-producing Enterobacteriaceae. *Numbers do not add up to 1847 because of missing values. Valid percentages are reported after 
removal of missing values, which were assumed to be random. †Numbers do not add up to 633 because of missing values. The demoninators for percentages are the numbers 
of travellers at risk given in the previous column. ‡Only adjusted for travel destination subregion, defi ned according to the United Nations geoscheme: Caribbean and Central 
America, middle and eastern Africa, central and eastern Asia, North America, Europe, and Oceania, southern Asia, southeastern Asia, western Asia, northern Africa, southern 
Africa, western Africa, and South America. §Adjusted for travel destination and travel variables shown in table. ¶Defi ned as ≥3 unformed stools within 24 h, with or without 
accompanying symptoms. ||Most frequently used to treat gastroenteritis (41 [31·1%] of 132 travellers), of whom 17 (41·5%) took them without consulting a doctor. 
Table 3: Predictors for ESBL-E acquisition among travellers in the fi nal adjusted logistic regression model
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second to travel destination, antibiotic use was the strongest 
predictor for ESBL-E acquisition, particularly quinolone 
use during travel. Pervasive disturbance in the human 
microbiota has been reported after ciprofl oxacin treat-
ment.16,20 For amoxicillin, although the eff ect on the human 
microbiota is moderate, an increase in the abundance of 
resistant Enterobacteriaceae has been reported after its 
use.16,19 Similar to other studies,21 antibiotics were mostly 
used to treat gastroenteritis. Counselling before travel to 
refrain from the use of antibiotics to treat self-limiting 
infections could reduce the import of ESBL-E by travellers. 
Kantele and colleagues,22 for example, showed that use of 
loperamide alone to treat mild traveller’s diarrhoea was not 
associated with an increased risk of ESBL-E colonisation.
The signifi cantly higher frequency of ESBL-E acquisition 
among travellers to Asia than other regions is probably due 
to the widespread dissemination of ESBL-E in these regions 
and high risk of food contamination. Diet-associated 
predictors, therefore, might diff er by travel destination, and 
might have been missed in previous studies that did not 
stratify data by destination. In the overall analysis, food 
consumption from street vendors was associated with an 
increased risk of ESBL-E acquisition, but in the stratifi ed 
analysis in southern Asia daily food consumption at a 
hostel or guesthouse and in southeastern Asia consumption 
of raw vegetables were predictive factors.
While the frequency of acquisition of ESBL-E by 
travellers is fairly consistent across studies, duration of 
carriage has varied from 5% to 24% at 6 months after 
return.6 In our study, we found that 65 (11·3%) of 
577 travellers who acquired ESBL-E during travel had 
sustained colonisation (persistent or intermittent) 
12 months after return. Although our study focused on 
asymptomatic carriage of ESBL-E, international travel has 
also been associated with ESBL-E infection among 
patients in the community and in hospital.23,24 Depending 
on the local policies, therefore, empirical adjustment of 
antimicrobial therapy should be considered in patients 
recently returned from international travel.
Our fi ndings suggest that strains or plasmids carrying 
CTX-M group 9 ESBL genes have a colonisation advantage 
that results in sustained carriage. This fi nding agrees with 
those from other studies showing sustained carriage 
associated with these genes in travellers returning from 
Asia, in the community and in hospital.25,26 Moreover, 
colonisation in this study was longer in travellers who 
acquired ESBL-producing E coli than in those with ESBL-
producing K pneumoniae. These observations might be 
explained by accessory colonisation factors, such as 
P-fi mbriae or aerobactin, or diff erences in fi tness costs and 
plasmid stability between E coli and K pneumoniae.27,28
Our mathematical model of onward transmission of 
ESBL-E in households of travellers, which took into 
account factors such as total number of household 
members, estimated 12% probability of transmission. 
In households of recently discharged patients, Hilty and 
colleagues29 reported transmission of ESBL-E to 
20 (22·7%) of 88 household contacts. This higher risk 
might be due to more frequent and longer exposure 
times of caregiving household members to discharged 
patients. Practising hand hygiene at home might lessen 
the risk of household transmission of ESBL-E.30
Our study has some potential limitations. First, as in 
most epidemiological studies, our study population was 
probably more affl  uent and healthy than the average for 
the general population, which could have led to selection 
that aff ected the frequency of ESBL-E acquisition and the 
statistical power and generalisability of the results. 
However, for bias to occur, selection would have to aff ect 
both the exposure and the outcome, which is unlikely in 
prospective cohort studies. Inferences drawn from 
our study are also unlikely to be aff ected by (selective) 
attrition, since loss to follow-up was minimal and 
12-month follow-up was achieved in 92·2% of 
participants after travellers returned. Second, faecal 
cross-contamination during collection of stool samples 
could theoretically have aff ected the estimations of 
colonisation and transmission. We aimed to keep the 
risk of cross-contamination to a minimum by providing 
participants with clear instructions for sample collection, 
including graphics. Lastly, although our results showed 
very low background transmission rates, in the absence 
of molecular typing of strains or mobile genetic elements 
harbouring ESBL genes, some overestimation of the 
duration of colonisation and household transmission 
due to novel ESBL-E acquisition from outside the 
household cannot be completely excluded.
320 million people visit Asia, northern Africa, and the 
Middle East per year3 and, therefore, international travel is 
expected to contribute substantially to the emergence and 
Figure 2: Kaplan-Meier estimate of time to decolonisation of ESBL-E 
in travellers
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spread of ESBL-E in travellers’ countries of origin. Taking 
into account the total number of Dutch travellers visiting 
these regions annually, we estimate that each year between 
3·0% and 7·1% of the Dutch population acquires an ESBL-E 
during travel to destinations outside Europe, northern 
America, and Oceania (appendix). Overall, with acquisition 
of 34·3% and sustained carriage after acquisition seen in 
11·3% of travellers 12 months after return, plus a 
12% probability of household transmissions, our fi ndings 
support the substantial contribution of international travel 
to the spread of ESBL-E and antimicrobial resistance 
worldwide. The degree of consequence of the emergence 
and spread of antimicrobial resistance by travellers, however, 
diff ers by region, and is highly dependent on local preval-
ence of antimicrobial resistance in the country of origin. 
Contributors
MSA and JMvH did the study, collected the data, and contributed to the 
study design. PJJvG, CS, HAV, MDdJ, DCM, and JP designed the study 
and are members of the supervising board. MRH, MCJB, AG, MPG, 
AMOL, NM, and EES contributed to the study design, data collection, or 
both. MSA, JMvH, MRH, MCJB, PJJvG, CS, HAV, MDdJ, DCM, and JP 
contributed to the data analysis and interpretation. MSA, JMvH, MRH, 
and JP drafted the Article with help from all authors. MSA, JMvH, 
MRH, MCJB, PJJvG, AG, MPG, CS, EES, HAV, MDdJ, DCM, and JP 
contributed to the critical revision of the drafts for important intellectual 
content. All authors read and approved the fi nal version of the paper.
Declaration of interests
We declare no competing interests.
Acknowledgments
This work was supported by Netherlands Organisation for Health 
Research and Development (ZonMw, grant number 205200003). 
We thank all the employees of the Travel Clinics (Institute for Tropical 
Diseases, Havenziekenhuis; Centre of Tropical Medicine and Travel 
Medicine, Academic Medical Centre; EASE Travel Health & Support) for 
their help in the recruitment of participants.
References
1 Appelbaum PC. 2012 and beyond: potential for the start of a second 
pre-antibiotic era? J Antimicrob Chemother 2012; 67: 2062–6 8.
2 El Salabi A, Walsh TR, Chouchani C. Extended spectrum 
beta-lactamases, carbapenemases and mobile genetic elements 
responsible for antibiotics resistance in Gram-negative bacteria. 
Crit Rev Microbiol 2013; 39: 113–22.
3 UNWTO. UNWTO tourism highlights, 2014 edition. Madrid: 
World Tourism Organization UNTWO, 2014 .
4 Carattoli A. Plasmids and the spread of resistance. Int J Med Microbiol 
2013; 303: 298–304.
5 Schultsz C, Geerlings S. Plasmid-mediated resistance in 
Enterobacteriaceae: changing landscape and implications for therapy. 
Drugs 2012; 72: 1–16.
6 Hassing RJ, Alsma J, Arcilla MS, van Genderen PJ, Stricker BH, 
Verbon A. International travel and acquisition of multidrug-resistant 
Enterobacteriaceae: a systematic review. Euro Surveill 2015; published 
online Nov 26, 2015. DOI:10.2807/1560-7917.ES.2015.20.47.3007 4.
7 Ruppe E, Armand-Lefevre L, Estellat C, et al. High rate of acquisition 
but short duration of carriage of multidrug-resistant 
Enterobacteriaceae after travel to the tropics. Clin Infect Dis 2015; 
61: 593–60 0.
8 Kantele A, Laaveri T, Mero S, et al. Antimicrobials increase travelers’ 
risk of colonization by extended-spectrum betalactamase-producing 
Enterobacteriaceae. Clin Infect Dis 2015; 60: 837–4 6.
9 Paltansing S, Vlot JA, Kraakman ME, et al. Extended-spectrum 
β-lactamase-producing Enterobacteriaceae among travelers from the 
Netherlands. Emerg Infect Dis 2013; 19: 1206–13.
10 Ostholm-Balkhed A, Tarnberg M, Nilsson M, Nilsson LE, 
Hanberger H, Hallgren A. Travel-associated faecal colonization with 
ESBL-producing Enterobacteriaceae: incidence and risk factors. 
J Antimicrob Chemother 2013; 68: 2144–5 3.
11 Arcilla MS, van Hattem JM, Bootsma MC, et al. The Carriage Of 
Multiresistant Bacteria After Travel (COMBAT) prospective cohort 
study: methodology and design. BMC Public Health 2014; 14: 41 0.
12 Bernards AT, Bonten MJM, Stuart JC, et al. NVMM guideline: 
laboratory detection of highly resistant microorganisms, 
version 2.0. Leeuwarden: Netherlands Society for Medical 
Microbiology, 201 2.
13 Bursac Z, Gauss CH, Williams DK, Hosmer DW. 
Purposeful selection of variables in logistic regression. 
Source Code Biol Med 2008; 3: 17.
14 Arcilla MS, van Hattem JM, Matamoros S, et al. Dissemination of 
the mcr-1 colistin resistance gene. Lancet Infect Dis 2016; 16: 147–4 9.
15 van Hattem JM, Arcilla MS, Bootsma MC, et al. Prolonged carriage 
and potential onward transmission of carbapenemase-producing 
Enterobacteriaceae in Dutch travelers. Future Microbiol 2016; 
11: 857–6 4.
16 Sullivan A, Edlund C, Nord CE. Eff ect of antimicrobial agents on 
the ecological balance of human microfl ora. Lancet Infect Dis 2001; 
1: 101–1 4.
17 Youmans BP, Ajami NJ, Jiang ZD, et al. Characterization of 
the human gut microbiome during travelers’ diarrhea. 
Gut Microbes 2015; 6: 110–1 9.
18 Sheehan D, Moran C, Shanahan F. The microbiota in 
infl ammatory bowel disease. J Gastroenterol 2015; 50: 495–50 7.
19 Jernberg C, Lofmark S, Edlund C, Jansson JK. Long-term impacts 
of antibiotic exposure on the human intestinal microbiota. 
Microbiology 2010; 156: 3216–2 3.
20 Dethlefsen L, Huse S, Sogin ML, Relman DA. The pervasive eff ects 
of an antibiotic on the human gut microbiota, as revealed by deep 
16S rRNA sequencing. PLoS Biol 2008; 6: e28 0.
21 Kantele A. A call to restrict prescribing antibiotics for travellers’ 
diarrhea—travel medicine practitioners can play an active role in 
preventing the spread of antimicrobial resistance. 
Travel Med Infect Dis 2015; 13: 213–1 4.
22 Kantele A, Mero S, Kirveskari J, Lääveri T. Increased risk for 
ESBL-producing bacteria from co-administration of loperamide 
and antimicrobial drugs for travelers’ diarrhea. Emerg Infect Dis 
2016; 22: 117–2 0.
23 Laupland KB, Church DL, Vidakovich J, Mucenski M, Pitout JD. 
Community-onset extended-spectrum β-lactamase (ESBL) 
producing Escherichia coli: importance of international travel. 
J Infect 2008; 57: 441–4 8.
24 Epelboin L, Robert J, Tsyrina-Kouyoumdjian E, Laouira S, 
Meyssonnier V, Caumes E. High rate of multidrug-resistant 
gram-negative bacilli carriage and infection in hospitalized 
returning travelers: a cross-sectional cohort study. J Travel Med 
2015; 22: 292–9 9.
25 Titelman E, Hasan CM, Iversen A, et al. Faecal carriage of 
extended-spectrum beta-lactamase-producing Enterobacteriaceae is 
common 12 months after infection and is related to strain factors. 
Clin Microbiol Infect 2014; 20: O508–1 5.
26 Barreto Miranda IDM, Ignatius RPDM, Pfuller RDM, et al. 
High carriage rate of ESBL-producing Enterobacteriaceae at 
presentation and follow-up among travellers with gastrointestinal 
complaints returning from India and Southeast Asia. 
J Travel Med 2016; 23: tav02 4.
27 Cottell JL, Webber MA, Piddock LJ. Persistence of transferable 
extended-spectrum-β-lactamase resistance in the absence of 
antibiotic pressure. Antimicrob Agents Chemother 2012; 56: 4703–0 6.
28 Nowrouzian FL, Adlerberth I, Wold AE. Enhanced persistence in 
the colonic microbiota of Escherichia coli strains belonging to 
phylogenetic group B2: role of virulence factors and adherence to 
colonic cells. Microbes Infect 2006; 8: 834–40.
29 Hilty M, Betsch BY, Bogli-Stuber K, et al. Transmission dynamics 
of extended-spectrum β-lactamase-producing Enterobacteriaceae 
in the tertiary care hospital and the household setting. 
Clin Infect Dis 2012; 55: 967–7 5.
30 Bloomfi eld SF, Cookson B, Falkiner F, Griffi  th C, Cleary V. 
Methicillin-resistant Staphylococcus aureus, Clostridium diffi  cile, and 
extended-spectrum beta-lactamase-producing Escherichia coli in the 
community: assessing the problem and controlling the spread. 
Am J Infect Control 2007; 35: 86–88.
